News | March 20, 2009

Phase 3 Data from Genetically Targeted Beta Blocker for Chronic Heart Failure Presented at ACC

March 20, 2009 - ARCA biopharma Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, said today two Gencaro (bucindolol hydrochloride) abstracts will be presented as poster sessions at the American College of Cardiology 58th Annual Scientific Session March 29-31, 2009 in Orlando, FL.

The abstracts present data from the pivotal Phase 3 BEST trial of Gencaro in patients with advanced chronic heart failure. Poster 170 is “All-Cause Mortality Endpoint Comparison in Large Beta-Blocker Heart Failure Trials: U.S. Versus Rest of World.” Christopher O’Connor, M.D., professor of medicine in the division of cardiology, chief of the division of clinical pharmacology in the department of medicine, and director of the Duke heart failure program at Duke University Medical Center, is scheduled to present a comparative analysis of U.S. versus ROW primary and other clinical endpoint data from the “MERIT,” “COPERNICUS,” and “BEST” trials in a poster presentation (ACC Poster Contributions 1024 – Myocardial Function/Heart Failure – Clinical Pharmacology) on Sunday, March 29, from 3:30 p.m. to 4:30 p.m. (eastern).

Poster 184 is “Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan.” Michael Bristow, M.D., ARCA’s founder and chief science and medical officer, is scheduled to present unpublished results of the pivotal Phase 3 BEST trial of Gencaro in patients with advanced chronic heart failure analyzed according to the pre-specified regulatory statistical analysis plan in a poster presentation (ACC Poster Contributions 1024 – Myocardial Function/Heart Failure – Clinical Pharmacology) on Sunday, March 29, 2009, from 3:30 p.m. to 4:30 p.m. (eastern).

Dr. Bristow will also participate in two panel discussions. “Pharmacogenomics and the Failing Heart.” ACC Symposium 604 – The Role of Genetic Testing in the Diagnosis and Management of Heart Failure will be held Sunday, March 29 from 10:30 a.m. to noon (eastern). The second discussion is ACC Meet the Experts 211 – Hemodynamic Monitoring in Implanted Arrhythmia Devices, Monday, March 30, from 11 a.m. to noon (eastern).

ARCA biopharma's lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The new drug application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. The company’s second compound in development, NU172, is a direct thrombin inhibitor, which has completed Phase 1b development for use as a potential short-acting anticoagulant during medical or surgical procedures.

For more information:

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init